Peter Attia Departs David Protein Amid Epstein Links, Focus Shifts to Biograph Longevity Startup

Attia’s Exit Sends Ripples Through the Longevity Ecosystem

On February 3, 2026 the founder of David Protein announced on X that Dr. Peter Attia, the high‑profile physician‑scientist known for his work on lifespan extension, has resigned from his position as Chief Science Officer. The departure follows the public release of more than 1,700 documents linking Attia to the late financier Jeffrey Epstein, a development that has already reshaped investor sentiment across the biotech and health‑tech sectors.

David Protein: From Protein Bar to $75 Million Series A

Founded in 2021, David Protein quickly became a household name with its flagship bar that delivers 28 grams of protein, zero sugar, and only 150 calories per serving. The company’s rapid growth attracted a $75 million Series A round in May 2025, led by Greenoaks and joined by Valor Equity Partners. This capital infusion enabled the brand to expand distribution nationwide and to explore science‑backed nutrition research—a mission that attracted Attia’s expertise.

Attia joined David Protein not only as an early investor but also to lend scientific credibility to its product pipeline. His involvement was highlighted in press releases and on the company’s website, positioning the brand at the intersection of nutrition and longevity science.

The Epstein Files and Their Impact on Attia’s Reputation

In late January 2026, the New York Times reported that a massive dump of Epstein‑related documents included over 1,700 files mentioning Peter Attia. While Attia publicly expressed “ashamed” feelings about the crude content of some emails, he maintained that he never engaged in illegal activity, never visited Epstein’s island, and never flew on his private jet.

These revelations prompted David Protein to issue a brief statement confirming Attia’s resignation and emphasizing the company’s continued commitment to scientific rigor. Simultaneously, Biograph—a stealth‑mode longevity startup co‑founded by Attia and entrepreneur John Hering—has removed references to Attia from its website, fueling speculation about his future involvement.

Biograph: A Premium Preventive‑Health Platform

Biograph emerged from stealth in 2025 with backing from Vy Capital, Human Capital, Alpha Wave, and WndrCo, alongside angel investors such as Balaji Srinivasan. The company offers concierge‑style health assessments, genetic‑risk profiling, and AI‑driven longevity recommendations for members paying between $7,500 and $15,000 annually.

Attia’s name was prominently featured in the original launch announcement, positioning him as a scientific co‑founder. However, after the Epstein file leak, the Biograph website now returns a “file not found” error for pages that once listed him, and the firm declined to comment on his current status.

What the Media Is Saying

For a detailed breakdown of the events, see the TechCrunch article that first reported Attia’s exit and the ensuing fallout at Biograph.

Why Health‑Tech Startups Look to Platforms Like UBOS

Startups navigating regulatory scrutiny and rapid product iteration often turn to low‑code AI platforms that accelerate development. The AI health tech article on UBOS explains how AI‑enhanced pipelines can shorten time‑to‑market for diagnostics and personalized nutrition solutions—exactly the challenges faced by companies like David Protein and Biograph.

UBOS offers a suite of tools that can be leveraged by longevity‑focused founders:

• UBOS platform overview – a unified environment for data ingestion, model training, and API deployment.
• Web app editor on UBOS – drag‑and‑drop UI builder for patient portals.
• Workflow automation studio – orchestrates lab‑result processing and notification flows.
• Enterprise AI platform by UBOS – scales predictive models for large member bases.

These capabilities align with the needs of longevity startups that must integrate genomics, wearable data, and AI‑driven risk scores while maintaining compliance.

UBOS Resources That Accelerate Longevity Innovation

Entrepreneurs can explore the UBOS templates for quick start, which include pre‑built pipelines for health‑data normalization, AI‑based biomarker extraction, and automated reporting. For inspiration, the UBOS portfolio examples showcase projects ranging from AI‑powered nutrition trackers to full‑stack tele‑medicine platforms.

Startups at the seed stage may find the UBOS for startups program especially valuable, offering discounted pricing and mentorship. Meanwhile, small‑to‑mid‑size businesses can leverage UBOS solutions for SMBs to embed AI without hiring a full data science team.

Pricing transparency is key; the UBOS pricing plans include a pay‑as‑you‑grow tier that matches the cash‑flow realities of biotech founders.

Template Marketplace: Building Blocks for Longevity Apps

UBOS’s marketplace hosts dozens of ready‑made AI applications that can be repurposed for longevity research:

• AI Article Copywriter – generate scientific blog posts and patient education material.
• AI Survey Generator – design and analyze participant questionnaires for clinical studies.
• AI Health Tech – a starter kit for building health‑monitoring dashboards.
• AI YouTube Comment Analysis tool – gauge public sentiment on longevity topics.
• AI SEO Analyzer – ensure your research portal ranks for key queries like “longevity biomarkers”.

By stitching together these modules, founders can launch MVPs in weeks rather than months, preserving runway for critical clinical validation.

Investor Sentiment After the Attia Announcement

Venture capitalists monitoring the longevity space have expressed heightened diligence. The biotech startups news feed notes a trend toward “clean‑room” due diligence, where firms scrutinize founder backgrounds more rigorously. While David Protein’s recent funding round remains intact, some limited partners are re‑evaluating exposure to founders with controversial histories.

For emerging companies, this environment underscores the importance of transparent governance and robust compliance frameworks—areas where low‑code platforms like UBOS can embed audit trails directly into data pipelines.

What Lies Ahead for Biograph and Longevity Startups?

Biograph’s next move will likely hinge on whether it can retain its investor base while clarifying Attia’s role. The company’s core value proposition—AI‑driven, high‑touch preventive health—remains compelling, especially as consumer willingness to spend on longevity services continues to rise.

Industry analysts predict that the longevity market will exceed $500 billion by 2035, driven by advances in genomics, wearable biosensors, and AI‑based risk modeling. Startups that can combine scientific rigor with scalable technology stacks will capture the lion’s share of this growth.

Platforms such as the About UBOS team emphasize that “AI democratization is the catalyst for the next wave of health innovation,” a sentiment echoed by many founders seeking to avoid the pitfalls that befell high‑profile ventures like David Protein.